Stimulation of angiotensin AT 2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats

British Journal of Pharmacology

Volumn 159, Issue 3, 2010, Pages 709-716

  Bosnyak, S ^a   Welungoda, I K ^a   Hallberg, A ^b   Alterman, M ^b   Widdop, R E ^a   Jones, E S ^a  

^a MONASH UNIVERSITY   (Australia)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiotensin; Angiotensin AT 2 receptor; Blood pressure; Compound 21; Spontaneously hypertensive rats; Vascular function

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; CANDESARTAN; COMPOUND 21; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; BENZIMIDAZOLE DERIVATIVE; IMIDAZOLE DERIVATIVE; PEPTIDE; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DEPRESSOR RESPONSE; DOSE RESPONSE; DRUG MECHANISM; IN VITRO STUDY; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; VASODILATATION; WISTAR KYOTO RAT; ANIMAL; BLOOD PRESSURE; BLOOD VESSEL; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; DRUG EFFECT; MOUSE STRAIN; PHYSIOLOGY;

ANIMALS; AORTA; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD VESSELS; CARDIOVASCULAR SYSTEM; CONSCIOUSNESS; IMIDAZOLES; MALE; MICE; MICE, INBRED STRAINS; PEPTIDES; PYRIDINES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; TETRAZOLES; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 76449117787     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00575.x     Document Type: Article

References (28)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 : S1 S209.
2. Barber MN, Sampey DB, Widdop RE (1999). AT2 receptor stimulation enhances antihypertensive effect of AT1 receptor antagonist in hypertensive rats. Hypertension 34 : 1112 1116.
3. Carey RM (2005). Update on the role of the AT(2) receptor. Curr Opin Nephrol Hypertens 14 : 67 71.
4. Carey RM, Howell NL, Jin X-H, Siragy HM (2001). Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension 38 : 1272 1277.
5. Cosentino F, Savoia C, De Paolis P, Francia P, Russo A, Maffei A et al. (2005). Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 18 : 493 499.
6. Dimitropoulou C, White RE, Fuchs L, Zhang HF, Catravas JD, Carrier GO (2001). Angiotensin II relaxes microvessels via the AT(2) receptor and Ca2+-activated K+ (BKCa) channels. Hypertension 37 : 301 307.
7. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T (2000). International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 : 415 472.
8. Gohlke P, Pees C, Unger T (1998). AT(2) receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31 : 349 355.
9. Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK (1995). Behavioral and cardiovascular effects of disrupting the angiotensin-ii type-2 receptor gene in mice. Nature 377 : 744 747.
10. Henrion D, Kubis N, Levy BI (2001). Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 38 : 1150 1157.
11. Ichiki T, Hogan BLM, Ichikawa I, Inagami T (1995). Targeted disruption of angiotensin-II type-2 receptor (AT2) gene. Hypertension 26 : 546 546.
12. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE (2008). AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 120 : 292 316.
13. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F et al. (2008). Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 118 : 2523 2532.
14. Li XC, Widdop RE (2004). AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR. Br J Pharmacol 142 : 821 830.
15. Loufrani L, Matrougui K, Gorny D, Duriez M, Blanc I, Levy BI et al. (2001). Flow (shear stress)-induced endothelium-dependent dilation is altered in mice lacking the gene encoding for dystrophin. Circulation 103 : 864 870.
16. Matrougui K, Loufrani L, Heymes C, Levy BI, Henrion D (1999). Activation of AT(2) receptors by endogenous angiotensin II is involved in flow-induced dilation in rat resistance arteries. Hypertension 34 : 659 665.
17. Matrougui K, Levy BI, Henrion D (2000). Tissue angiotensin II and endothelin-1 modulate differently the response to flow in mesenteric resistance arteries of normotensive and spontaneously hypertensive rats. Br J Pharmacol 130 : 521 526.
18. Savoia C, Tabet F, Yao GY, Schiffrin EL, Touyz RM (2005). Negative regulation of RhoA/Rho kinase by angiotensin II type 2 receptor in vascular smooth muscle cells: role in angiotensin II-induced vasodilation in stroke-prone spontaneously hypertensive rats. J Hypertens 23 : 1037 1045.
19. Savoia C, Touyz RM, Volpe M, Schiffrin EL (2007). Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension 49 : 341 346.
20. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S et al. (1999). Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104 : 925 935.
21. Walters PE, Gaspari TA, Widdop RE (2005). Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45 : 960 966.
22. Wan Y, Wallinder C, Johansson B, Holm M, Mahalingam AK, Wu X et al. (2004a). First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo. J Med Chem 47 : 1536 1546.
23. Wan YQ, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu XY et al. (2004b). Design, synthesis, and biological evaluation of the first selective nonpeptide AT(2) receptor agonist. J Med Chem 47 : 5995 6008.
24. Widdop RE, Matrougui K, Levy BI, Henrion D (2002). AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 40 : 516 520.
25. Widdop RE, Jones ES, Hannan RE, Gaspari TA (2003). Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 140 : 809 824.
26. Widdop RE, Vinh A, Henrion D, Jones ES (2008). Vascular angiotensin AT2 receptors in hypertension and ageing. Clin Exp Pharmacol Physiol 35 : 386 390.
27. Yayama K, Horii M, Hiyoshi H, Takano M, Okamoto H, Kagota S et al. (2004). Up-regulation of angiotensin II type 2 receptor in rat thoracic aorta by pressure-overload. J Pharmacol Exp Ther 308 : 736 743.
28. You D, Loufrani L, Baron C, Levy BI, Widdop RE, Henrion D (2005). High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 111 : 1006 1011.